$955 Million is the total value of Bain Capital Life Sciences Investors, LLC's 15 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRSN | New | MERSANA THERAPEUTICS, INC. | $80,629,000 | – | 3,445,667 | +100.0% | 8.44% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS, INC. | $24,975,000 | – | 2,700,000 | +100.0% | 2.62% | – |
| SAGE | New | SAGE THERAPEUTICS, INC. | $20,753,000 | – | 499,100 | +100.0% | 2.17% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS, INC. | $18,771,000 | – | 1,071,428 | +100.0% | 1.97% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, LP #2
- BC SW, LP #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SAVARA INC | 19 | Q2 2024 | 6.4% |
| X4 PHARMACEUTICALS INC | 19 | Q2 2024 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 18 | Q2 2024 | 20.1% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| MERSANA THERAPEUTICS, INC. | 17 | Q2 2024 | 8.4% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| ANNEXON INC | 16 | Q2 2024 | 9.1% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-12 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.